High Tide Forecasts Record Q3 2026 Results, Beating Analyst Expectations
Event summary
- High Tide expects Q3 2026 revenue between $195M and $200M, exceeding analyst consensus of $185.3M.
- Gross profit projected at $51M–$53.5M, with Adjusted EBITDA ranging from $15.2M to $16.5M.
- Remexian Pharma distributed over 10 tonnes of medical cannabis in Q3, a 33% sequential and 60% year-over-year increase.
- Canadian retail business saw positive same-store sales growth in June and July.
The big picture
High Tide's Q3 guidance highlights its dual-engine growth strategy, combining a resilient Canadian retail platform with rapid scaling in Germany. The company's ability to outperform analyst expectations underscores the strength of its integrated cannabis operations amid a competitive market landscape. This performance positions High Tide as a key player in both the North American and European cannabis sectors.
What we're watching
- Market Expansion
- How High Tide's German medical cannabis distribution will scale amid regulatory shifts.
- Operational Efficiency
- Whether the Canadian retail business can sustain positive same-store sales growth.
- Financial Performance
- The pace at which High Tide can convert revenue growth into higher Adjusted EBITDA margins.
Related topics